Search

Your search keyword '"Wischnewsky, M."' showing total 228 results
Start Over Author "Wischnewsky, M."
228 results on '"Wischnewsky, M."'

59. Coronary computed tomography angiography indicates complexity of percutaneous coronary interventions

Author

Stähli, B E, Bonassin, F, Goetti, R, Küest, S M, Frank, M, Altwegg, L A, Gebhard, C, Levis, A, Wischnewsky, M B, Lüscher, T F, Alkadhi, H, Kaufmann, P A, Maier, W, Stähli, B E, Bonassin, F, Goetti, R, Küest, S M, Frank, M, Altwegg, L A, Gebhard, C, Levis, A, Wischnewsky, M B, Lüscher, T F, Alkadhi, H, Kaufmann, P A, and Maier, W

Abstract

BACKGROUND: Coronary computed tomography angiography (CCTA) provides information regarding lesion morphology and three-dimensional coronary anatomy incremental to coronary angiography. We addressed the question whether preprocedural CCTA bears potential for guiding percutaneous coronary interventions (PCI). METHODS AND RESULTS: Sixty-six coronary lesions attempted with PCI within 6 months of preprocedural CCTA were retrospectively assessed. Lesion parameters from unenhanced computed tomography (CT) for calcium scoring and CCTA were analyzed and compared with PCI complexity. Complex PCI was defined as use of buddy wire, kissing balloon, necessity of high pressure balloons, or rotablator. Complex PCIs were observed in 32 interventions (48%). Median Agatston score and Hounsfield units were higher in lesions with complex as compared to those with non-complex interventions with 130 (interquartile range, 23-276) vs 29 (0-158; P=.01), and 493 (245-631) vs 341 (68-520 Hounsfield Units; P=.04), respectively. Median local plaque volume and plaque mass were higher in complex PCI with 17 (2-39) vs 5 (0-19.5 mm³; P=.007), and 48 (15-99) vs. 16 (1.5-63 mg hydroxyapatite/mm³; P=.03), respectively. Lesions leading to complex PCI were longer [1.8 (1.2-2.8) vs 1.3 (0.8-1.7) cm; P=.03], and had a higher rate of calcified plaques (23% vs 3%; P=.03). There was a significant correlation between CCTA- and angiography-derived local SYNTAX Scores (P<.001); the CCTA-derived score seems to be predictive for failed and complex PCI (area under curve = 0.75 ± 0.13 and 0.66 ± 0.08, respectively). CONCLUSIONS: Preprocedural lesion assessment by CCTA indicates complexity of PCI. In patients with suspected complex coronary anatomy, prior CCTA adds important information for planning PCI.

Published
2012

60. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes

Author

Wyss, C A, Neidhart, M, Altwegg, L, Spanaus, K S, Yonekawa, K, Wischnewsky, M B, Corti, R, Kucher, N, Roffi, M, Eberli, F R, Amann-Vesti, B, Gay, S, von Eckardstein, Arnold, Lüscher, T F, Maier, W, Wyss, C A, Neidhart, M, Altwegg, L, Spanaus, K S, Yonekawa, K, Wischnewsky, M B, Corti, R, Kucher, N, Roffi, M, Eberli, F R, Amann-Vesti, B, Gay, S, von Eckardstein, Arnold, Lüscher, T F, and Maier, W

Abstract

AIMS: Inflammation plays a key role in acute coronary syndromes (ACS). Toll-like receptors (TLR) on leucocytes mediate inflammation and immune responses. We characterized leucocytes and TLR expression within coronary thrombi and compared cytokine levels from the site of coronary occlusion with aortic blood (AB) in ACS patients. METHODS AND RESULTS: In 18 ACS patients, thrombi were collected by aspiration during primary percutaneous coronary intervention. Thrombi and AB from these patients as well as AB from 10 age-matched controls without coronary artery disease were assessed by FACS analysis for cellular distribution and TLR expression. For further discrimination of ACS specificity, seven non-coronary intravascular thrombi and eight thrombi generated in vitro were analysed. In 17 additional patients, cytokine levels were determined in blood samples from the site of coronary occlusion under distal occlusion and compared with AB. In coronary thrombi from ACS, the percentage of monocytes related to the total leucocyte count was greater than in AB (47 vs. 20%, P = 0.0002). In thrombi, TLR-4 and TLR-2 were overexpressed on CD14-labelled monocytes, and TLR-2 was increased on CD66b-labelled granulocytes, in comparison with leucocytes in AB. In contrast, in vitro and non-coronary thrombi exhibited no overexpression of TLR-4. Local blood samples taken under distal occlusion revealed elevated concentrations of chemokines (IL-8, MCP-1, eotaxin, MIP-1alpha, and IP-10) and cytokines (IL-1ra, IL-6, IL-7, IL-12, IL-17, IFN-alpha, and granulocyte-macrophage colony-stimulating factor) regulating both innate and adaptive immunity (all P < 0.05). CONCLUSION: In ACS patients, monocytes accumulate within thrombi and specifically overexpress TLR-4. Together with the local expression patterns of chemokines and cytokines, the increase of TLR-4 reflects a concerted activation of this inflammatory pathway at the site of coronary occlusion in ACS.

Published
2010

61. ONCO-CONS (ONCO-DOC, ONCO-HELP)

Author

Wischnewsky, M. B.

Subjects
Medizininformatik, Expertensysteme, Onkologie, ddc:80
Abstract

München

Published
1998

70. trueCase

Author

Ogurol, Y, Jutzies, P, Angilletta, S, Lund, M, Laue, H, Novopashenny, I, Wischnewsky, M, Ogurol, Y, Jutzies, P, Angilletta, S, Lund, M, Laue, H, Novopashenny, I, and Wischnewsky, M

Published
2004

92. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes

Author

Altwegg, L. A., primary, Neidhart, M., additional, Hersberger, M., additional, Muller, S., additional, Eberli, F. R., additional, Corti, R., additional, Roffi, M., additional, Sutsch, G., additional, Gay, S., additional, von Eckardstein, A., additional, Wischnewsky, M. B., additional, Luscher, T. F., additional, and Maier, W., additional

Published
2007
Full Text
View/download PDF

93. Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer.

Author

O'Leary, K, Shia, A, Cavicchioli, F, Haley, V, Comino, A, Merlano, M, Mauri, F, Walter, K, Lackner, M, Wischnewsky, M B, Crook, T, Lo Nigro, C, and Schmid, P

Subjects
LUNG cancer & genetics, ENDOGLIN, EPIGENETICS, TRANSFORMING growth factors-beta, TUMOR suppressor genes, DNA methylation, ANTIGENS, BIOCHEMISTRY, CELL lines, CELL receptors, GENES, LUNG cancer, LUNG tumors, PHENOMENOLOGY, METHYLATION, ONCOGENES, DISEASE progression, PROTEIN microarrays, SEQUENCE analysis
Abstract

Background: The transforming growth factor-beta (TGF- β) pathway has been implicated in proliferation, migration and invasion of various cancers. Endoglin is a TGF-β accessory receptor that modulates signalling. We identified Endoglin as an epigenetically silenced tumour-suppressor gene in lung cancer by means of a genome-wide screening approach, then sought to characterise its effect on lung cancer progression. Methods: Methylation microarray and RNA sequencing were carried out on lung cancer cell lines. Epigenetic silencing of Endoglin was confirmed by methylation and expression analyses. An expression vector and a 20-gene expression panel were used to evaluate Endoglin function. Pyrosequencing was carried out on two independent cohorts comprising 112 and 202 NSCLC cases, respectively, and the impact of Endoglin methylation on overall survival (OS) was evaluated. Results: Methylation in the promoter region resulted in silencing of Endoglin, which could be reactivated by demethylation. Increased invasion coupled with altered EMT marker expression was observed in cell lines with an epithelial-like, but not those with a mesenchymal-like, profile when Endoglin was absent. Methylation was associated with decreased OS in stage I but not in stages II-III disease. Conclusions: We show that Endoglin is a common target of epigenetic silencing in lung cancer. We reveal a link between Endoglin silencing and EMT progression that might be associated with decreased survival in stage I disease. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

94. Up front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC): Final results of a randomized trial

Author

Schmid, P., primary, Schippinger, W., additional, Nitsch, T., additional, Huebner, G., additional, Kreienberg, R., additional, Schultze, W., additional, Hausmaninger, H., additional, Wischnewsky, M., additional, Samonigg, H., additional, and Possinger, K., additional

Published
2004
Full Text
View/download PDF

98. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients.

Author

Wolters, R., Wöckel, A., Janni, W., Novopashenny, I., Ebner, F., Kreienberg, R., Wischnewsky, M., and Schwentner, L.

Abstract

Multifocal (MF) and multicentric (MC) breast cancers have been comprehensively studied, and their outcomes have been compared with unifocal (UF) tumors. We attempted to answer the following questions: (1) Does MF/MC presentation influence the outcome concerning BC mortality?, (2) Is there an impact of guideline-adherent adjuvant treatment in these BC subtypes?, and (3)What is the influence of guideline violations concerning surgery (breast-conserving surgery versus mastectomy) on the survival of MF/MC BC patients? Between 1992 and 2008, we retrospectively analyzed 8,935 breast cancer patients from 17 participating breast cancer centers within the BRENDA study group. Of 8,935 breast cancer patients, 7,073 (79.2 %) had UF tumors, 1,398 (15.6 %) had MF tumors, and 464 (5.2 %) had MC tumors. RFS was significantly worse for MF/MC BC patients compared to patients with UF tumors (MF p = 0.007; MC p = 0.019). OAS was significantly worse for MC patients but not for MF patients compared to patients with UF tumors (MF p = 0.321; MC p = 0.001). Guideline adherence was significantly lower in patients with MF ( n = 580; 41.5 %) and MC ( n = 204; 44.0 %) compared to patients with UF ( n = 3,871; 54.7 %) ( p < 0.001) tumors. Guideline violations were associated with a highly significant deterioration in survival throughout all subgroups except for MC, with respect to RFS and OAS. For 100 %-guideline-adherent patients, we could not find any significant differences in RFS and OAS after adjusting by nodal status, grade, and tumor size. Furthermore, we could not find any significant differences in RFS and OAS in patients with MF or MC stratified by breast-conserving therapy ( BCT lumpectomy and radiation therapy) and mastectomy. There is a strong association between improved RFS and OAS in patients with MF/MZ BC. There are no significant differences in RFS and OAS for patients with breast-conserving therapy or mastectomy. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results